The epidemiology of gastroesophageal reflux disease: What we know and what we need to know

American Journal of Gastroenterology

Volumn 96, Issue 8 SUPPL., 2001, Pages

  Eisen, Glenn ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034881479     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02580-1     Document Type: Note

References (26)

1. Why do apparently healthy people use antacid tablets?
2. Update in gastroenterology
3. Clinical spectrum and diagnosis of gastroesophageal reflux disease
4. Muscular equivalent of the lower esophageal sphincter
5. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment
6. An evidence-based appraisal of reflux disease management - The Genval Workshop Report
7. Limitations of 24 hr intra-esophageal pH monitoring in the hospital setting
8. Does the intraesophageal pH probe accurately detect acid reflux? Simultaneous recording with two pH probes in humans
9. Gastroesophageal reflux disease and Barrettís esophagus
10. Symptoms in gastro-oesophageal reflux disease
11. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain
12. The natural history of gastroesophageal reflux
13. Symptomatic gastroesophageal reflux: Incidence and precipitating factors
14. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmstead County, Minnesota
15. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients
16. Three to 4.5 year prospective study of prognostic indicators in gastro-oesophageal reflux disease
17. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis
18. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
19. Association between body mass and adenocarcinoma of the esophagus and gastric cardia
20. The relation between gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
21. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
22. Continuing climb in rates of esophageal carcinoma: An update
23. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
24. Opposing time trends of peptic ulcer and reflux disease
25. Patterns of endoscopy in the United States